These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease. Matsuoka K; Hamada S; Shimizu M; Nanki K; Mizuno S; Kiyohara H; Arai M; Sugimoto S; Iwao Y; Ogata H; Hisamatsu T; Naganuma M; Kanai T; Mochizuki M; Hashiguchi M PLoS One; 2018; 13(10):e0204632. PubMed ID: 30286108 [TBL] [Abstract][Full Text] [Related]
24. Dissecting the Mechanisms of Intestinal Immune Homeostasis by Analyzing T-Cell Immune Response in Crohn's Disease and Colorectal Cancer. Jiang T; Zheng J; Li N; Li X; He J; Zhou J; Sun B; Chi Q Curr Gene Ther; 2024; 24(5):422-440. PubMed ID: 38682449 [TBL] [Abstract][Full Text] [Related]
25. Investigating regulatory patterns of NLRP3 Inflammasome features and association with immune microenvironment in Crohn's disease. Wu H; Zeng R; Qiu X; Chen K; Zhuo Z; Guo K; Xiang Y; Yang Q; Jiang R; Leung FW; Lian Q; Sha W; Chen H Front Immunol; 2022; 13():1096587. PubMed ID: 36685554 [TBL] [Abstract][Full Text] [Related]
26. Expression of CD40 and its ligand, CD40L, in intestinal lesions of Crohn's disease. Battaglia E; Biancone L; Resegotti A; Emanuelli G; Fronda GR; Camussi G Am J Gastroenterol; 1999 Nov; 94(11):3279-84. PubMed ID: 10566730 [TBL] [Abstract][Full Text] [Related]
27. Comparison of RANTES expression in Crohn's disease and ulcerative colitis: an aid in the differential diagnosis? Ansari N; Abdulla J; Zayyani N; Brahmi U; Taha S; Satir AA J Clin Pathol; 2006 Oct; 59(10):1066-72. PubMed ID: 16565224 [TBL] [Abstract][Full Text] [Related]
28. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium. Pedersen G Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335 [TBL] [Abstract][Full Text] [Related]
29. A comprehensive review and update on Crohn's disease. Gajendran M; Loganathan P; Catinella AP; Hashash JG Dis Mon; 2018 Feb; 64(2):20-57. PubMed ID: 28826742 [TBL] [Abstract][Full Text] [Related]
30. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy. Nørgård BM Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578 [TBL] [Abstract][Full Text] [Related]
31. Genetic determinants associated with early age of diagnosis of IBD. Connelly TM; Berg AS; Harris L; Brinton D; Deiling S; Koltun WA Dis Colon Rectum; 2015 Mar; 58(3):321-7. PubMed ID: 25664710 [TBL] [Abstract][Full Text] [Related]
32. Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease. Szanto I; Rubbia-Brandt L; Kiss P; Steger K; Banfi B; Kovari E; Herrmann F; Hadengue A; Krause KH J Pathol; 2005 Oct; 207(2):164-76. PubMed ID: 16086438 [TBL] [Abstract][Full Text] [Related]
33. Natalizumab for induction of remission in Crohn's disease. Macdonald JK; McDonald JW Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112 [TBL] [Abstract][Full Text] [Related]
35. MicroRNAs as Innovative Biomarkers for Inflammatory Bowel Disease and Prediction of Colorectal Cancer. Masi L; Capobianco I; Magrì C; Marafini I; Petito V; Scaldaferri F Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887337 [TBL] [Abstract][Full Text] [Related]
36. Targeted Notararigo S; Martín-Pastor M; Viñuela-Roldán JE; Quiroga A; Dominguez-Munoz JE; Barreiro-de Acosta M J Mol Med (Berl); 2021 Sep; 99(9):1251-1264. PubMed ID: 34021361 [TBL] [Abstract][Full Text] [Related]
37. Whole genome gene expression meta-analysis of inflammatory bowel disease colon mucosa demonstrates lack of major differences between Crohn's disease and ulcerative colitis. Granlund Av; Flatberg A; Østvik AE; Drozdov I; Gustafsson BI; Kidd M; Beisvag V; Torp SH; Waldum HL; Martinsen TC; Damås JK; Espevik T; Sandvik AK PLoS One; 2013; 8(2):e56818. PubMed ID: 23468882 [TBL] [Abstract][Full Text] [Related]
38. Natalizumab for induction of remission in Crohn's disease. MacDonald JK; McDonald JW Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580 [TBL] [Abstract][Full Text] [Related]
39. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Satsangi J; Welsh KI; Bunce M; Julier C; Farrant JM; Bell JI; Jewell DP Lancet; 1996 May; 347(9010):1212-7. PubMed ID: 8622450 [TBL] [Abstract][Full Text] [Related]
40. Identification of platelet-related subtypes and diagnostic markers in pediatric Crohn's disease based on WGCNA and machine learning. Tang D; Huang Y; Che Y; Yang C; Pu B; Liu S; Li H Front Immunol; 2024; 15():1323418. PubMed ID: 38420127 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]